N/A N=29 Role of the Gut Microbiome on Lean Mass and Physical Function in Older Adults
Sarcopenia
Primary: Percentage of Whole Body Lean Mass (%WBLM) — 67.3; 61.9 % of whole body mass
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=60 Fecal Microbiota Transplantation for Pancreatitis
Acute Pancreatitis · Intestinal Bacteria Flora Disturbance · Intestinal Dysfunction
Primary: Number of Participants With Gastrointestinal Failure Score Equal 0 — 12; 14 Participants
Phase 1 N=44 Intestinal Permeability in Preterm Infants
Prematurity · Intestinal Permeability
Primary: Intestinal Permeability — 0.0731; 0.0720 ratio — p=0.932
Phase 4 N=10 Effect of Antibiotics on Enteric Neurons and Glia
Antibiotic Enterocolitis
Primary: Change in Mean Number of Colonic Submucosal Neurons/mm^2 in the Colon After Antibiotic Treatment — 0 neuronal cells/mm^2
N/A N=22 Aging and Gastrointestinal Barrier Function
Aging · Hyperthermia
Primary: Log Lactulose/Rhamnose Following Control Trial — 0.97; 0.79 Ratio
N/A N=39 Biomarkers for Intestinal Permeability in Patients With Constipation
Intestinal Diseases · Irritable Bowel Syndrome · Constipation
Primary: Lactulose:C13 Mannitol Excretion Ratio 8-24hrs. — 0.01; 0.02 Ratio — p=0.87
Phase 1 N=12 Effect of Prebiotics on the Gut Microbiome Profile and Beta Cell Function
Type 1 Diabetes
Primary: Change in the Gut Microbiome Profile — 818.5; 229; 1610; 177 species count
N/A N=16 Diet Induced Intestinal Mucosal Adaptation
Healthy Conditions
Primary: Mucosal Surface Enlargement — 10.2; 9.9 percentage of muscular mucosae — p=<0.05
Phase 1 N=21 Gastrointestinal Microbiota in Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin
Primary Sclerosing Cholangitis · Biliary Atresia
Primary: Determine the Benefit of Oral Vancomycin Therapy for Primary Sclerosing Cholangitis and Biliary Atresia — 10; 0; 0; 0 participants
N/A N=92 Dietary Supplement With and Without a Probiotic and/or Antibiotic
Healthy Adults
Primary: Evaluation of the Changes in Microbiome Species Abundance and Diversity From Baseline Until End of Study (Day 35) — 27.00; 31.25; 27.00; 27.00 copies/ng DNA — p=<0.0001
N/A N=369 Defining the Intestinal Microbiota in Premature Neonates
Premature Intestinal Microbiota · Necrotizing Enterocolitis · Late Onset Bloodstream Infection
Primary: The Composition of Bacteria Present, Established by Ultra-deep RNA Gene Sequencing, in Pre-morbid Faecal Samples From Neonates With Necrotizing Enterocolitis and…
N/A N=62 Dietary Supplement With and Without a Probiotic
Healthy Adult Subjects
Primary: Evaluation of the Levels of B.Infantis in Stool by Quantitative PCR — 3.33; 3.33; 3.33; 3.33 copies/ng DNA — p=<0.0001
Phase 2 N=27 Investigation of the Gut Microbiota in Regulating Nutrient Absorption in Humans
Obesity
Primary: Stool Calories During OF and UF — 5.8; 8.9 percentage of calorie intake
Phase 4 N=14 Effects of Gastric Acid on Colonic Microbiome
Clostridium Difficile
Primary: Shannon Diversity Index Measuring Change in Microbiome Diversity — 0.18; 0.14 Shannon index — p=0.71
Phase 2 N=24 Fermented Milk Drink on Human Intestinal Microflora
Signs and Symptoms, Digestive
Primary: Modification of the Composition of the Intestinal Microflora: Bifidobacterium — 7.88; 7.60; 8.13; 8.10 log10 CFU/g — p=<0.05
N/A N=32 Assessment of Colonic Epithelial Integrity With Mucosal Impedance
Inflammatory Bowel Diseases
Primary: Mucosal Impedance Values — 1139; 849; 891; 783 ohms
N/A N=107 Use of a Novel Synbiotic to Change Human Gut Bacteria and Improve Health in Obese Adults
Intestinal Microbiota and Barrier Function
Primary: Change in Microbiota, as Measured by Change in Microbiota Composition, Including Presence of B. Adolescentis BD1 and B. Animalis Supsp Lactis BB-12 — 7.9; 9.1; 8.8; 6.0…
N/A N=225 Advanced Metagenomic Analysis of Human Colonic Microbiota in Patients With Chronic GI Disorders
Irritable Bowel Syndrome · Colitis, Ulcerative · Crohn Disease
Primary: Colonic-Mucosa Associated Microbial Species Per Compiled Participants in 5 Different Arms — 40; 30; 23; 23 microbial species population
N/A N=51 Impact of Consumption of Beta-glucans on the Intestinal Microbiota and Glucose and Lipid Metabolism
Metabolic Syndrome · Dyslipidemia · Obesity, Abdominal
Primary: Total Cholesterol Levels — 5.8; 5.9 mmol/L
N/A N=87 Modulation of the Intestinal Microbiome by a High Protein Diet
Obesity
Primary: Weight Loss (% Change) in Response to Dietary Intervention Change — -3.83; -3.89 percentage weight change from baseline
Phase 2 N=61 Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim2)
Insulin Sensitivity
Primary: Insulin Sensitivity — 10.16; 8.45; 9.47; 5.96 M Value (mg/kg/min) — p=<0.025
Phase 1 N=23 Fecal Microbiota Transplantation in Pediatric Patients
Inflammatory Bowel Diseases (IBD) · Crohn's Disease (CD) · Ulcerative Colitis (UC)
Primary: Number of Occurrences of Adverse Events at 6 Months According to Adverse Event Term — 11; 5; 5; 3 Events
Phase 2 N=12 Understanding the Role of Gut Microbiota in Hyperphagia in Prader-Willi Syndrome
Prader-Willi Syndrome · Obesity
Primary: Microbiome Analysis: Alpha Diversity — 4.89 Shannon index
N/A N=32 Effects of Pre-, Pro- & Anti-biotics on Gut Microbiota
Human Gut Microbiota
Primary: Bacteria Prevalence in Stool — 22.3; 20.9; 18.0; 25.5 percentage of bacterial genera in stool — p=<0.05
N/A N=30 Obesity - Inflammation - Metabolic Disease: Effect of Lactobacillus Casei Shirota
Metabolic Syndrome
Primary: Change of Neutrophil Phagocytosis From Baseline to 3 Months — 0.06; 3.48 percentage of monocytes and granulocytes
N/A N=35 Gut Organoid and Microbiome Interactions in Hypertension
Gut Inflammation · Hypertension
Primary: Differential Gene Expression in Gut Epithelium — 29; 6 Differentially expressed gene
Phase 4 N=89 Probiotics to Promote Intestinal Health
Communicable Diseases · Infection · Anti-Infective Agents
Primary: Number of Participants With Acquisition of Any New Antibiotic-resistant Organism — 9; 12 Participants
N/A N=49 Probiotics for Liver Cirrhosis With Portal Hypertension
Liver Cirrhosis · Portal Hypertension
Primary: Admission Due to Complications Related to Portal Hypertension — 2; 3 participants — p=0.25
Phase 2 N=94 Inulin for Infections in the Intensive Care Unit
Antibiotic Resistant Infection · Nosocomial Infection · Pathogen Transmission
Primary: Within-individual Change in SCFA Producer Level — -0.0; -1.8; 1.1 percentage of SCFA producers
Phase 4 N=153 The Effect of Probiotics on Constipation, and Intestinal Microflora in Children With Functional Constipation
Functional Constipation
Primary: Change of Clostridium Butyricum Miyairi Expression After Probiotics Supplementation in Constipated Children. — 0.00486; 0.0000148; 0.00000189 number of bacteria per mg…